These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tenecteplase in wake-up ischemic stroke trial: Protocol for a randomized-controlled trial. Roaldsen MB; Lindekleiv H; Eltoft A; Jusufovic M; Søyland MH; Petersson J; Indredavik B; Tveiten A; Putaala J; Christensen H; Kõrv J; Jatužis D; Engelter ST; Marco De Marchis G; Wilsgaard T; Werring DJ; Robinson T; Mathiesen EB; Berge E Int J Stroke; 2021 Oct; 16(8):990-994. PubMed ID: 33446083 [TBL] [Abstract][Full Text] [Related]
4. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250 [TBL] [Abstract][Full Text] [Related]
5. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502 [TBL] [Abstract][Full Text] [Related]
6. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit-TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit. Bivard A; Zhao H; Coote S; Campbell B; Churilov L; Yassi N; Yan B; Valente M; Sharobeam A; Balabanski A; Dos Santos A; Ng F; Langenberg F; Stephenson M; Smith K; Bernard S; Thijs V; Cloud G; Choi P; Ma H; Wijeratne T; Chen C; Olenko L; Davis SM; Donnan GA; Parsons M BMJ Open; 2022 Apr; 12(4):e056573. PubMed ID: 35487712 [TBL] [Abstract][Full Text] [Related]
8. Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial. Sajobi TT; Arimoro OI; Ademola A; Singh N; Bala F; Almekhlafi MA; Deschaintre Y; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz GJ; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar JS; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra SM; Gioia LC; Jalini S; Cayer C; Phillips SJ; Elamin E; Shoamanesh A; Subramaniam S; Kate MP; Jacquin G; Camden MC; Benali F; Alhabli I; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe AY; Sehgal A; Zhang Q; Lethebe B; Doram C; Shamy M; Kenney C; Buck BH; Swartz RH; Menon BK Stroke; 2024 Mar; 55(3):524-531. PubMed ID: 38275116 [TBL] [Abstract][Full Text] [Related]
9. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. Bivard A; Zhao H; Churilov L; Campbell BCV; Coote S; Yassi N; Yan B; Valente M; Sharobeam A; Balabanski AH; Dos Santos A; Ng JL; Yogendrakumar V; Ng F; Langenberg F; Easton D; Warwick A; Mackey E; MacDonald A; Sharma G; Stephenson M; Smith K; Anderson D; Choi P; Thijs V; Ma H; Cloud GC; Wijeratne T; Olenko L; Italiano D; Davis SM; Donnan GA; Parsons MW; Lancet Neurol; 2022 Jun; 21(6):520-527. PubMed ID: 35525251 [TBL] [Abstract][Full Text] [Related]
10. Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial. Xiong Y; Campbell BCV; Fisher M; Schwamm LH; Parsons M; Li H; Pan Y; Meng X; Zhao X; Wang Y Stroke Vasc Neurol; 2024 Feb; 9(1):82-89. PubMed ID: 37247876 [TBL] [Abstract][Full Text] [Related]
11. Statistical Analysis Plan for EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) trial. Churilov L; Ma H; Campbell BC; Davis SM; Donnan GA Int J Stroke; 2020 Feb; 15(2):231-238. PubMed ID: 30523735 [TBL] [Abstract][Full Text] [Related]
12. A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design. Albers GW; Campbell BC; Lansberg MG; Broderick J; Butcher K; Froehler MT; Schwamm LH; Nouh AM; Liebeskind DS; Toy F; Yang M; Massaro L; Schoeffler M; Purdon B Int J Stroke; 2023 Feb; 18(2):237-241. PubMed ID: 35262424 [TBL] [Abstract][Full Text] [Related]
13. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236 [TBL] [Abstract][Full Text] [Related]
14. Advances in the management of acute ischemic stroke. Nair R; Wagner AN; Buck BH Curr Opin Neurol; 2023 Apr; 36(2):147-154. PubMed ID: 36762632 [TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP). Thomalla G; Fiebach JB; Østergaard L; Pedraza S; Thijs V; Nighoghossian N; Roy P; Muir KW; Ebinger M; Cheng B; Galinovic I; Cho TH; Puig J; Boutitie F; Simonsen CZ; Endres M; Fiehler J; Gerloff C; Int J Stroke; 2014 Aug; 9(6):829-36. PubMed ID: 23490032 [TBL] [Abstract][Full Text] [Related]
16. Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations. Hailu K; Cannon C; Hayes S Am J Health Syst Pharm; 2022 Jun; 79(12):944-949. PubMed ID: 35020806 [TBL] [Abstract][Full Text] [Related]
17. Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke: An Analysis of the WAKE-UP Randomized Clinical Trial. Schlemm L; Braemswig TB; Boutitie F; Vynckier J; Jensen M; Galinovic I; Simonsen CZ; Cheng B; Cho TH; Fiehler J; Puig J; Thijs V; Fiebach J; Muir K; Nighoghossian N; Ebinger M; Pedraza S; Thomalla G; Gerloff C; Endres M; Lemmens R; Nolte CH; Neurology; 2022 Jan; 98(3):e302-e314. PubMed ID: 34782419 [TBL] [Abstract][Full Text] [Related]
18. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. Campbell BCV; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Dowling RJ; Yan B; Bush SJ; Thijs V; Scroop R; Simpson M; Brooks M; Asadi H; Wu TY; Shah DG; Wijeratne T; Zhao H; Alemseged F; Ng F; Bailey P; Rice H; de Villiers L; Dewey HM; Choi PMC; Brown H; Redmond K; Leggett D; Fink JN; Collecutt W; Kraemer T; Krause M; Cordato D; Field D; Ma H; O'Brien B; Clissold B; Miteff F; Clissold A; Cloud GC; Bolitho LE; Bonavia L; Bhattacharya A; Wright A; Mamun A; O'Rourke F; Worthington J; Wong AA; Levi CR; Bladin CF; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM; JAMA; 2020 Apr; 323(13):1257-1265. PubMed ID: 32078683 [TBL] [Abstract][Full Text] [Related]
19. Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study. Campbell BC; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Yan B; Thijs V; Desmond PM; Parsons MW; Donnan GA; Davis SM Int J Stroke; 2020 Jul; 15(5):567-572. PubMed ID: 31564231 [TBL] [Abstract][Full Text] [Related]